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OBJECTIVE — We explored the possibility that perturbations in amniotic ﬂuid glucose,
insulin, and insulin-like growth factor–binding protein 1(IGFBP1) and/or metabolic acids exist
before routine screening for GDM.
RESEARCH DESIGN AND METHODS — We selected consenting mother-infant pairs
(n408)whometourinclusioncriteria(singletonpregnancy,nogeneticabnormalities,andno
preexisting diabetes) and for whom sufﬁcient amniotic ﬂuid and appropriate medical informa-
tion were available. We compared birth outcomes and second trimester amniotic ﬂuid glucose,
insulin, IGFBP1 concentrations, and amniotic ﬂuid lactic, -hydroxybutyric, and uric acids of
mothers with gestational diabetes mellitus (GDM) (n  52) with those of mothers with no
diagnosis of GDM at 24 weeks (n  356).
RESULTS — Higher amniotic ﬂuid glucose, lactic acid, uric acid, and insulin and lower
IGFBP1 concentrations were present by 15.1  0.1 weeks in mothers in whom GDM was
subsequently diagnosed. However, logistic regression showed that second trimester amniotic
ﬂuid glucose, but not insulin, IGFBP1, or metabolic acids was associated with an increased odds
ratio(1.2[95%CI1.052–1.338])fordiagnosisofGDMat24–28weeks.Inaddition,probability
contour maps that accounted for nonlinear relationships among the dynamically changing
amniotic ﬂuid constituents showed an increased risk for GDM with elevated second trimester
amnioticﬂuidglucoseincombinationwitheitherelevatedamnioticﬂuidinsulinorlowamniotic
ﬂuid IGFBP1
CONCLUSIONS — Fetusesareexposedtoincreasedamnioticﬂuidglucosebefore15weeks
of gestation, suggesting that metabolic perturbations are underway before diagnosis and that
earlier screening and intervention may be warranted.
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G
estational diabetes mellitus (GDM)
is deﬁned as a state of hyperglyce-
mia arising during gestation that
leads to increased glucose delivery to the
developingfetus.Glucoseisconsideredto
be the principal metabolic fuel and sup-
plies 50–80% of fetal glucose needs (1)
with amniotic ﬂuid supplying another
10–15% via fetal swallowing (2). Report-
edly, amniotic ﬂuid glucose concentra-
tions are higher in mothers with type 1 or
type 2 diabetes than in those without di-
abetes (3) and in those with GDM than in
those without GDM (4). Amniotic ﬂuid
insulin is also elevated in mothers with
GDM versus those without GDM (4–6).
Some have suggested that amniotic ﬂuid
insulin may be a more sensitive early pre-
dictor of GDM than amniotic ﬂuid glu-
cose, but neither has emerged as an early
screening tool (4). More recently, pertur-
bations in insulin-like growth factors and
their binding proteins have been impli-
cated in diabetic pregnancies (7). In
particular, lower concentrations of insu-
lin-like growth factor–binding protein 1
(IGFBP1) in maternal plasma during the
secondtrimesterbeforediagnosisofGDM
(8) and an inverse relationship with cord
blood IGFBP1 of mothers with GDM at
term and birth weight (9) have been
described.
It is well known that GDM is associ-
ated with poor perinatal outcomes, with
macrosomia, and with a higher preva-
lence of diabetes in the offspring of moth-
ers with GDM (10,11), but how soon
duringdevelopmentthesefetalinsultsbe-
gin is not clear. Two recent studies have
linkedsubsequentdiagnosisofGDMwith
irreversible oxidative damage to amniotic
ﬂuid albumin (12) and to lacticacidemia
and fetal hypoxia in cord blood at term
even in mothers with well-controlled
GDM (13). Mothers with GDM also show
evidence of altered ketogenesis and
higher circulating concentrations of
-hydroxybutyrate that may be linked to
increased gluconeogenesis and not to
-oxidation (14) and to increased uric
acid (15) that could be related to hypoxia
that often occurs with diabetes.
GDM is usually diagnosed between
24 and 28 weeks of gestation by an oral
glucose tolerance test (OGTT) (16). In
this study, we explore the possibility that
early fetal exposure to perturbations in
second trimester amniotic ﬂuid glucose,
insulin, and IGFBP 1 and/or amniotic
ﬂuid lactic, -hydroxybutyric, and uric
acids may exist before current routine
screening for GDM.
RESEARCH DESIGN AND
METHODS— From 2000 to 2004,
pregnant women undergoing age-related
amniocentesis for genetic testing at St
Mary’s Hospital Center (Montreal, QC,
Canada) were approached to participate
in this study. Signed consents allowed re-
searchers to collect frozen amniotic ﬂuid
samplesandtoreviewmedicalrecordsaf-
ter genetic testing. Application of exclu-
sion criteria (multiple births, genetic
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2 diabetes) resulted in 408 mother-infant
pairs having birth weights, gestational
age, and sex recorded in the maternal
chart and for whom the screening for and
diagnosisofGDMusinga1-h50-gOGTT
at 24–28 weeks of pregnancy was per-
formed with a cutoff of 10.3 mmol/l for
diagnosis of GDM, which was in place at
the time of our recruitment. At present a
value of 10.3 mmol/l is still used to di-
agnose GDM (16). Ethics approval was
obtained from McGill University and St
Mary’s Hospital Centre.
Prepregnancy weight and height, age,
smoking status (1  yes and 0  never or
quit before pregnancy), parity, infant sex,
birth weight, and gestational age were
veriﬁed from medical charts. Gestational
age at both the time of amniocentesis and
at parturition was calculated based on
physicians’ estimates using last menstrual
period. Ethnicity was classiﬁed as Cauca-
sian, Asian, or other. Maternal prepreg-
nancy BMI was categorized into four
groups: 18.5 kg/m
2 for underweight,
18.5–24.9 kg/m
2 for normal, 24.9–29.9
kg/m
2foroverweight,and30kg/m
2for
obese.
Biochemical analyses
Frozen amniotic ﬂuid samples (80°C)
were analyzed for glucose, insulin, and
IGFBP1. Insulin was analyzed using the
Beckman Access ultrasensitive assay sys-
tem (Beckman Coulter, Brea, CA), a one-
step immunoenzymatic assay that adds a
monoclonal anti-insulin conjugate, anti-
body-coated paramagnetic particles, and
a chemiluminescent substrate to the reac-
tion vessel. This new, more speciﬁc, assay
measures insulin to within 0.03–300
IU/l.Glucosewasanalyzedafteradapta-
tion of a hexokinase assay kit (No. 6082;
Abbott Laboratories, North Chicago, IL)
for use with a microplate reader. Total
IGFBP1 was measured by ELISA (DSL kit
10-7800; Diagnostics Systems Laborato-
ries, Webster, TX).
The three metabolic acids were mea-
sured as follows: -hydroxybutyric acid
by procedure 310-UV (reagent 310-3,
-hydroxybutyric dehydrogenase solu-
tion 310-4, and -hydroxybutyric acid
calibratorsolution310-50;SigmaAldrich
Canada,Oakville,ON,Canada);uricacid
by the A-gent chemistries (reagent 6184,
standards 6008-02, procedure 69-0163;
AbbottLaboratoriesDiagnosticsDivision,
North Chicago, IL); and lactic acid by
procedure 735 (Sigma-Aldrich). All kits
were adapted for microplate assay. -Hy-
droxybutyric and uric acids were read at
355nmusingaVictor2platereader(Wal-
lac; Gaithersburg, MD, a subdivision of
PerkinElmer Life and Analytical Sciences,
Boston, MA), and lactate was read in a
BioTek reader (BioTek Instruments, Wi-
nooski, VT) at 540 nm.
Statistical analyses
All data analyses were performed using
SAS (version 9.1; SAS, Cary, NC) with
P  0.05 set as the minimum for statisti-
cal signiﬁcance. All nonnormally distrib-
uted continuous data were transformed
using square root (amniotic ﬂuid glucose
and gestational age at time of amniocen-
tesis) and logarithmic processing
(prepregnancyweight,BMI,andamniotic
ﬂuid insulin). We performed ANCOVA,
controlling for maternal BMI, age, infant
sex, smoking, and parity and where re-
quired for amniocentesis week and eth-
nicity for each of our amniotic ﬂuid
constituents if there were signiﬁcant dif-
ferences between the populations with
and without GDM. Separate logistic re-
gressions for GDM with each amniotic
ﬂuid constituent entered individually in
the model were performed; factors
known to contribute to the emergence of
GDM(BMI,maternalage,parity,andeth-
nicity) (16) were also included in each
logistic regression model.
In addition, Bayesian contour maps
were created to assess risk for GDM be-
cause this approach did not presume a
linear relationship and would account for
metabolic interrelationships resulting
from these dynamically changing amni-
otic ﬂuid constituents. Each outcome
(GDM vs. non-GDM) was separately
modeled with Gaussian mixture model-
ing and an expectation maximization of a
log-likelihood procedure that uses a quasi-
Newton algorithm written in Matlab V6.5
(Mathworks). The posteriori distribu-
tions were plotted as contour maps for
which lines of equal height in the joint
density function were created using the
measured data (17). Speciﬁcity, sensitiv-
ity, and accuracy for each contour map
were evaluated using the maximum pos-
teriori probability for assignment of an
outcome. Speciﬁcity was calculated as
number of true negatives/number of true
negatives  number of false positives.
Sensitivity was calculated as number of
true positives/number of true positives 
number of false negatives. Accuracy was
calculated as number of true correct pre-
dictions/total number of individuals.
RESULTS— A total 408 pregnant
mothers were screened for GDM at 24
weeks gestation; 52 (11.3%) met the Ca-
nadian Diabetes Association (2008) crite-
riaforGDMwitha1-h50-gOGTT10.3
mmol/l (16). Otherwise, our multiethnic
population (64% Caucasian, 20% Asian,
and 16% other) were healthy, nonsmok-
ing (84%) mothers who delivered infants
with a mean birth weight of 3,462  22 g
at term (39.5  0.07 weeks). Compari-
sons for insulin and IGFBP1 according to
week of pregnancy when amniocentesis
was performed (12–23 weeks; 15.2 
0.03) showed that amniotic ﬂuid insulin
concentrationscollectedinwomenwhose
amniocentesisweredoneafter16.5weeks
were higher than those in women having
amniocentesis performed before 15.5
weeks, and IGFBP1 was higher after 15.5
weeks than at earlier time points. In con-
trast, amniotic ﬂuid glucose and -hy-
droxybutyric, lactate, and uric acid
concentrations did not differ across these
weeks of gestation (data not presented).
Comparisons between mothers with
and without GDM and their offspring are
reported in Table 1. Mothers with GDM
were older, shorter, and heavier; in fact
the proportion of overweight (BMI 26
kg/m
2) in mothers with vs. without GDM
was 36 vs. 19% and for obese mothers
(BMI 30 kg/m
2) was 21 vs. 7%, respec-
tively (P  0.0001). Of interest, a higher
proportion of mothers with GDM were
Asian (46 vs. 16% in the non-GDM
group; P  0.05). Parity did not differ
between mothers with and without GDM
(P  0.0699). Offspring of mothers with
GDM were heavier (3510 vs. 3445 g; P 
0.05) and had a higher sex-corrected
birth-weight-for-gestational-age percen-
tile (64.8  3.7 vs. 51.6  1.4%; P 
0.05). Markedly more infants of mothers
with GDM were born large for gestational
age (21 vs. 7%; P  0.05) even though
these infants were born earlier than their
non-GDM counterparts (39.0  0.21 vs.
39.6  0.07 weeks; P  0.05). Despite
these differences, the majority of infants
were born appropriate for gestational age
in our non-GDM (88.5%) and GDM
groups (75.1%). On average, GDM was
associated with a 176-g increase in birth
weight in a multiple linear regression that
controlled for maternal prepregnancy
weight and height, smoking behavior,
gestational age, parity, and infant sex.
This model captured 32% of the variabil-
ity in infant birth weight.
Mothers with GDM had higher sec-
ond trimester amniotic ﬂuid glucose, lac-
Amniotic ﬂuid glucose and insulin
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IGFBP1 (Table 1). Inclusion of one or
moreofthefollowingcovariates,maternal
BMI, age, ethnicity, parity, smoking be-
havior, infant sex, and gestational age at
the time of amniocentesis, did not alter
these signiﬁcant relationships for glucose
and insulin but did for IGFBP 1. We were
able to show that both maternal age and
ethnicity explained the difference in am-
niotic ﬂuid IGFBP1 concentrations be-
tween mothers with and without GDM
because inclusion of age and ethnicity as
covariates eliminated the signiﬁcant dif-
ference between these two groups. When
we subdivided our amniotic ﬂuid constit-
uents by ethnicity, we also observed that
Asians had higher insulin (0.70  0.05
vs. 0.54  0.02 pmol/l) and lower
IGFBP1 (27,949  2,974 vs. 37,472 
1,814 g/ml) than Caucasians; other eth-
nic groups had intermediate concentra-
tions that did not differ. Amniotic ﬂuid
glucosedidnotdifferbyethnicity.Finally
multivariate logistic regression revealed
that maternal BMI, age, ethnic origin, and
increased second trimester amniotic ﬂuid
glucosewereallassociatedwithincreased
odds of mothers developing GDM (i.e.,
10.3, 16.4, 81.1, and 18.6%, respec-
tively) (Table 2). Neither amniotic ﬂuid
insulin (odds ratio 1.679 [95% CI 0.915–
3.081]), IGFBP1 (1.00 [1.00–1.00]), nor
metabolic acids entered as a signiﬁcant
independent predictor in similar models
for GDM.
Because of the metabolic interrela-
tionship of amniotic ﬂuid glucose with
both amniotic ﬂuid insulin and amniotic
ﬂuid IGFBP1, we explored the possibility
thatchangesinoneamnioticﬂuidconstit-
uent could inﬂuence the concentration of
the other. We presumed that the interre-
lationshipswouldbenonlinearandthere-
fore used two-dimensional probability
plots to explore potential metabolic inter-
relationships with pairs of amniotic ﬂuid
constituents. Two sets of contour maps
for risk of GDM were created that paired
amnioticﬂuidglucosewithamnioticﬂuid
insulin (Fig. 1A) and amniotic ﬂuid glu-
cose with amniotic ﬂuid IGFBP1 (Fig.
1B). The contour map combining amni-
otic ﬂuid glucose with amniotic ﬂuid in-
sulin (Fig. 1A) showed that high amniotic
ﬂuid glucose (7.5 mmol/l) in combina-
tion with high amniotic ﬂuid insulin
(1.5pmol/l)wasassociatedwith80%
risk of mothers subsequently having a di-
agnosisofGDM.Italsoshowedthatatany
glucoseconcentration,anelevationto1.5
pmol/l in amniotic ﬂuid insulin increased
the likelihood of mothers having a diag-
nosis of GDM; 4.6% of our mothers who
developed GDM met these criteria. The
accuracy for our glucose and insulin con-
tour map was 68%, its speciﬁcity was
74%, and its sensitivity was 27%. Our
second contour map (Fig. 1B) comparing
amniotic ﬂuid glucose with IGFBP1
showedthathigheramnioticﬂuidglucose
(7.5mmol/l)incombinationwithlower
concentrations of amniotic ﬂuid IGFBP1
(3g/ml)wereassociatedwithahigher
risk of mothers subsequently having a di-
agnosisofGDM.Thiscontourmaphadan
accuracyof64%,aspeciﬁcityof68%,and
asensitivityof38%.Weconcludedonthe
basisofourspeciﬁcitycomparedwithour
sensitivity measurements that we were
more likely to “identify” those mothers
who would not develop GDM than pre-
dict its later emergence.
CONCLUSIONS — Population char-
acteristics and pregnancy outcomes of
Table 1—Maternal, infant, and amniotic ﬂuid characteristics for mother-infant pairs with
GDM at >24 weeks vs. those without GDM
Characteristics Non-GDM GDM P value
Maternal
Height (m) 1.62  0.004 1.60  0.01 0.0136
Prepregnancy weight (kg) 61.9  0.62 67.5  2.9 0.0231
BMI (kg/m
2) 23.4  0.21 26.3  1.0 0.0001
% overweight (BMI 25–30 kg/m
2) 19 36
% obese (BMI 30 kg/m
2) 72 1
Parity 1.1  0.05 1.4  0.14 0.0699
Maternal age (years) 37.8  0.13 38.7  0.32 0.0155
Infant
Gestational age at birth (week) 39.6  0.07 39.0  0.21 0.0062
Birth weight (g) 3,445  23 3,581  77 0.0408
% AGA 88.5 75.1
% LGA 7 21
Birth weight for gestational age
(% ranking) 51.6  1.4 64.8  3.7 0.0008
Amniotic ﬂuid
Amniocentesis week 15.1  0.05 15.3  0.16 0.1324
Glucose (mmol/l)* 3.84  0.12 5.61  0.47 0.0001
Insulin (pmol/l)* 0.57  0.02 0.86  0.13 0.0001
IGFBP1 (g/ml)* 35,602  1,578 25,856  3,308 0.0246
Lactic acid (mmol/l)* 7.9  0.1 8.8  0.3 0.0061
-Hydroxybutyric acid (mol/l)* 220  6.7 231  21 0.6968
Uric acid (mol/l)* 173  4.3 204  13 0.0142
Data are reported as means  SEM. Maternal prepregnancy weight, BMI, gestational week of amniocentesis,
and amniotic ﬂuid insulin, glucose, and -hydroxybutyric acid were either square-root or log transformed
to normalize skewness and kurtosis. AGA, appropriate for gestational age; LGA, AGA, large for gestational
age. *Covariates for amniotic ﬂuid variables included maternal BMI, smoking, parity, age, ethnicity, and
week of amniocentesis. P  0.05.
Table 2—Logistic regression for GDM
Characteristic Odds ratio (95% CI)
Maternal prepregnancy BMI (kg/m
2) 1.103 (1.034–1.176)
Maternal age (years) 1.164 (1.019–1.330)
Maternal ethnicity 1.811 (1.225–2.679)
Amniotic ﬂuid glucose (mmol/l) 1.186 (1.052–1.338)*
Amniotic ﬂuid insulin (pmol/l) 1.679 (0.915–3.081)*
Amniotic ﬂuid IGFBP1 (g/ml) 1.00 (1.00–1.00)*
-Hydroxybutyric acid (mol/l) 1.00 (0.99–1.001)*
*Amniotic ﬂuid constituents were included one at a time in different GDM logistic regression models.
Glucose was the only signiﬁcant amniotic ﬂuid constituent that predicted a later diagnosis of GDM because
the95%CIdidnotpassthrough1.ThemodelcontrolledforprepregnancyBMI,maternalage,andethnicity,
where parity and smoking were also entered but were not signiﬁcant. n  386.
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cal of the Canadian population at large.
Theuseofsecondtrimesteramnioticﬂuid
glucose and insulin as prognosticators for
GDM has previously been investigated in
a few studies but with variable results
(4,6,18). Our study, with its larger popu-
lation,resultedinfourmajorﬁndings.We
showed that 1) GDM, which occurred in
lean, overweight, and obese women, was
associated with a 176-g increase in birth
weight in our study population, 2) amni-
otic ﬂuid glucose, lactic and uric acids,
and insulin were elevated by 15 weeks
whereas IGFBP1 was decreased in moth-
ers subsequently having a diagnosis of
GDM, 3) despite perturbations in insulin,
IGFBP1, and metabolic acids, only amni-
otic ﬂuid glucose was associated with an
increased odds of mothers developing
GDM once all other risk factors were con-
trolled for, and 4) two-dimensional con-
tour maps that classiﬁed amniotic ﬂuid
glucose in combination with either amni-
oticﬂuidinsulinorIGFBP1werebetterat
“ruling out” GDM than in “predicting” its
occurrence. These results underscore the
existenceofearlymetabolicperturbations
in amniotic ﬂuid glucose that may be re-
lated to dynamic changes in insulin and
IGFBP1 early in pregnancy in mothers
subsequently having a diagnosis of GDM.
There is evidence to show that early
elevationinamnioticﬂuidglucose,which
the fetus swallows, may be problematic.
Early exposure to elevated glucose can
lead to irreversible oxidation of albumin
by 15 weeks of gestation in mothers with
GDM (12) and to accelerated exhaustion
of -cells (19). Our study showed that
amniotic ﬂuid glucose was already ele-
vated in our population with GDM by
15.20.1weeksofgestation,whichsup-
ports a previous study (4). However, it is
not yet clearly established that fetal hy-
perinsulinemia is actually driven by fetal
hyperglycemia (4). One study showed
that amniotic ﬂuid glucose was not asso-
ciated with fetal hyperinsulinism before
23 weeks of gestation (20), but another
study reported increased amniotic ﬂuid
insulin in a diabetic pregnancy (6). By re-
lating amniotic ﬂuid glucose to insulin in
contour maps, we were able to show that
amniotic ﬂuid glucose and insulin are in-
terrelated and that elevations in both are
associated with a later diagnosis of GDM.
It had been suggested that amniotic
ﬂuid insulin might be a better predictor
than amniotic ﬂuid glucose of impaired
glucose tolerance in mothers with GDM
(4). Insulin release by the human fetus
occursasearlyas11weeksandisfoundin
higher concentrations in the second tri-
mester of mothers with diabetes (21) and
in those with GDM (4,6,18). Our study
revealed that amniotic ﬂuid insulin was
elevated in our mothers with GDM, but
amnioticﬂuidinsulin,incontrasttothese
earlier studies (4,6,18), did not enter as a
signiﬁcant independent predictor in our
multiple linear regression models when
we controlled for maternal age, prepreg-
nancy BMI, gestational age at the time of
amniocentesis, and ethnicity. Each is
knowntomodulateamnioticﬂuidinsulin
concentrations. Interestingly, when we
did plot our amniotic ﬂuid insulin with
our amniotic ﬂuid glucose in our contour
maps, we also observed that our sensitiv-
ity was reasonably low (27%), but that
our speciﬁcity was reasonably high
(68%), which supports previous reports
(4) that neither was robust enough to
screen for the diagnosis of GDM. What
our probability plots suggest is that using
combinations of second trimester amni-
otic ﬂuid glucose and insulin would more
reliably “rule out” GDM than diagnose it.
IGFBP1, found in abundance in sec-
Figure 1—A: Class-conditional Bayesian a posteriori probability density plotted as a contour
map for amniotic ﬂuid glucose paired with amniotic ﬂuid insulin. B: Similar class-conditional
Bayesian a posteriori probability density contour map for second trimester amniotic ﬂuid glucose
and IGFBP1. E, mean for the population without GDM; , mean for the population with GDM.
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sociated in cord blood with an inverse
relationship with birth weight in mothers
with GDM at term (9). Our contour maps
also showed that low amniotic ﬂuid
IGFBP1 in the presence of high glucose
wasassociatedwithahigherriskofdevel-
oping GDM; 30% of our mothers with
GDM met these criteria. Our ﬁndings ex-
tend to amniotic ﬂuid the previously re-
ported relationship for low maternal
plasma IGFBP1 with elevated risk of
GDM (8). Prior studies have also shown
that Asians are more susceptible to
GDM (22). Asians reportedly have
lower concentrations of plasma IGFBP1
(8). In our study population, we also
observed that a higher proportion of
Asians had GDM and amniotic ﬂuid
IGFBP1 was lower in these mothers
withGDM.Uponcontrollingforethnic-
ity, this difference was lost, which fur-
ther supports observations that Asian
mothers have lower levels of amniotic
ﬂuid IGFBP1. When highly phosphory-
lated IGFBP1 is lower in GDM pregnan-
cies, more free IGF-I may be available,
and together these changes could ac-
count for the inverse association of
IGFBP1 with birth weight (23).
Whether the fundamental change rep-
resents a genetic difference or the early
emergence of a metabolic dysregulation
in a subset of the mothers with GDM
requires further exploration.
Some limitations to the application of
our ﬁndings are in order. We caution
against using the exact glucose, insulin,
and IGFBP1 concentrations presented in
the contour maps because they were cre-
ated using biobanked samples. Others
have shown that there is a slight progres-
sive decline (4%) in the concentrations of
amniotic ﬂuid glucose and an increase in
insulinasaresultofstorageat20°C(4).
Once GDM is diagnosed, mothers receive
treatment. Undoubtedly, these interven-
tionsaredirectedtoloweringbirthweight
and decreasing the incidence of macroso-
mia. Thus, both the incidence of macro-
somia and an average increase in birth
weightrelatedtoGDMinourstudycould
be underestimated. Finally, our data
show that although our accuracy is rea-
sonably high at 64–68% for each of our
probability plots, our sensitivity is low
(27–38%); this would indicate that there
are probably other factors that are re-
quired to diagnose GDM this early in
pregnancy. For now, our concentrations
could be used to rule out GDM with a
speciﬁcity of 68–74%.
In summary, we show that in the ab-
sence of an impaired glucose tolerance
test, amniotic ﬂuid glucose, insulin, and
IGFBP1 concentrations can be perturbed
by 15 weeks of gestation, some 10 weeks
earlier than current screening in pregnant
mothers who later develop GDM. These
perturbations are also associated with an
increased birth weight of at least 176 g,
which may not necessarily be related to
the delivery of a large-for-gestational-age
infant, and, therefore, focusing on ultra-
sound measurements of abdominal cir-
cumference (24) although important,
maynotbetheonlyclinicalindicator.The
possibility that combined early elevations
in amniotic ﬂuid glucose and insulin and
lowerIGFBP1mightbeclinicallyusefulis
supported by our ﬁndings. Our results
show that metabolic perturbations found
in amniotic ﬂuid early in pregnancy may
underscorethehigherincidenceofdiabe-
tesseeninoffspringofmotherswithGDM
later in life (11). We suggest that earlier
screeningforGDMusingmeasuresofam-
niotic ﬂuid glucose and insulin in moth-
ers undergoing age-related amniocentesis
may be warranted.
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